Glucagon-Like Peptide (GLP)-1 Agonists in Diabetes and Obesity: Management of Patients Taking GLP-1 Medications

This presentation will list the currently available glucagon-like peptide (GLP-1) agonists in the United States, and summarize their mechanisms of action, indications and contraindications, adverse effects and cost. We will then review the results of the FDA-mandated cardiovascular outcomes trials comparing these drugs with placebo, focusing on their long-term outcomes in subjects with diabetes and/or obesity. Lastly, we will recommend several methods of mitigating their adverse effects when prescribed in the daily practice of medicine.

Dr. Elliott Faculty Disclosure

The Washington Osteopathic Medical Association is accredited by the American Osteopathic Association as a Category 1 CME Sponsor. 
The WOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements.
Comments, questions, or complaints should be forwarded to WOMA Executive Director, Roseanne Andersen, by calling the WOMA office at 425-677-3930, by mail to WOMA, P.O. Box 1187, Gig Harbor, WA 98332, or by email to executivedirector@woma.org.